Hand-curated array provides complete coverage of over 4600 medically relevant genes
Oxford, UK – 14 October 2014. Oxford Gene Technology (OGT), The Molecular Genetics Company, will launch its CytoSure™ Medical Research Exome Array at the 64th Annual Meeting of the American Society of Human Genetics (ASHG) 2014, taking place in San Diego on October 18-22.
Developed with leading molecular genetics experts at Emory University, the new array is highly targeted and exon-focussed, enabling the accurate detection of medical research relevant microdeletions and microduplications. The high-density array (1x1M) contains over 4,600 hand-curated genes, which have been grouped into disease- and syndrome-specific panels. This research-validated gene content can also be customised for varying array formats (2x400K, 4x180K or 8x60K) and diseases, enabling researchers to create bespoke solutions to suit both their content and throughput requirements.
Genetic disorders are rarely caused by an isolated mutation within a single gene, and one or many genes can contribute to one or multiple disorders. It is therefore vital to assess many different genes in order to gain a true picture of the underlying genetic landscape. OGT’s new array meets the needs of the medical research community by providing coverage of hand-curated, medically relevant genes on one array, enabling the detection of single or multiple exonic copy number variations (CNVs). As such, the array is an ideal complement to other genomic technologies, such as next generation sequencing (NGS), to provide accurate analysis of the full mutation spectrum. James Clough, Executive Vice President Commercial at OGT, said: “The new CytoSure Medical Research Exome Array is the latest addition to OGT’s portfolio and is another example of our commitment to providing high-quality and reliable tools to advance and improve research. The hand-curated, customisable and research-validated gene content, was made possible through OGT’s much-valued collaboration with leading molecular genetics experts at Emory University.”
At ASHG, OGT is inviting delegates to a workshop titled ‘Arrays and NGS — High Resolution Analysis of the Medical Exome’ on October 20 at 14.45 in the Exhibit Theatre. Speakers include Professor of Human Genetics, Madhuri Hegde, Executive Director at Emory Genetics Laboratory and Dr Mike Evans, Chief Executive, OGT. Attendees of the workshop will hear about the development of OGT’s new CytoSure Medical Research Exome Array and how this technology is being used to complement NGS and Sanger sequencing for the accurate detection of point mutations and single exon copy number aberrations.
Delegates can also visit booths 320 and 322 to find out more about the new range of Cytocell® FISH probes, the CytoSure range of constitutional, molecular and cancer arrays and the new SureSeq™ Solid Tumour NGS Panel.
To reserve your place at the workshop email contact@ogt.com or visit www.ogt.com/ASHG2014. For more information on the CytoSure Medical Research Exome Array please visit the OGT website.
For further information, please contact:
Oxford Gene Technology, Begbroke Science Park, Begbroke Hill, Woodstock Road, Begbroke, Oxfordshire, OX5 1PF, U.K. T: +44 (0) 1865 856826 ; F: +44 (0) 1865 848684
E: contact@ogt.com ; W: www.ogt.com ; Twitter: @OxfordGeneTech
Notes for editors:
About Oxford Gene Technology
Oxford Gene Technology (OGT) provides world-class genetics research solutions to leading clinical and academic research institutions. Founded by Professor Sir Edwin Southern, and with customers in over 60 countries worldwide, OGT has a strong reputation and increasing share in the large and growing genomic medicine market. The Company’s Cytocell®, CytoSure™, SureSeq™ and Genefficiency™ range of fluorescence in situ hybridisation (FISH), microarray and next generation sequencing (NGS) products and services deliver high-quality genetic analysis, enabling accurate identification and confirmation of the causative variation underlying genetic disease. For more information on the Company, please visit our website at www.ogt.com
CytoSure™, SureSeq and Genefficiency™ NGS browser/report: For Research Use Only; Not for Use in Diagnostic Procedures
CytoSure: This product is provided under an agreement between Agilent Technologies, Inc., and OGT. The manufacture, use, sale or import of this product may be subject to one or more of U.S. patents, pending applications, and corresponding international equivalents, owned by Agilent Technologies, Inc. The purchaser has the non-transferable right to use and consume the product for RESEARCH USE ONLY AND NOT for DIAGNOSTICS PROCEDURES. It is not intended for use, and should not be used, for the diagnosis, prevention, monitoring, treatment or alleviation of any disease or condition, or for the investigation of any physiological process, in any identifiable human, or for any other medical purpose.
Media enquiries
Alto Marketing Limited
Victoria Coupe – Senior Account Manager (Life Science)
t: +44 (0)1489 557672
e: victoriac@alto-marketing.com
Twitter: @AltoMarketing
w: www.alto-marketing.com
Help employers find you! Check out all the jobs and post your resume.
